The clinical site agreement is a positive but early-stage milestone for a development-stage biotech with no revenue. Monitor for additional site announcements, trial initiation, and enrollment updates. The stock's small cap and low liquidity may amplify any news-driven moves, but the path to commercialization remains long and uncertain.
Price Chart
Executive Summary
Polyrizon announced signing its first Clinical Trial Agreement (CTA) with a U.S.-based clinical site in Texas for the NASARIX (PL-14) Allergy Blocker, a key milestone toward initiating first-in-human clinical trials. The planned multi-center study will evaluate safety, tolerability, and efficacy in seasonal allergic rhinitis patients, but the company remains a development-stage biotech with no approved products or revenue.
Key Facts
- Signed first Clinical Trial Agreement (CTA) with a U.S.-based clinical site in Texas for NASARIX (PL-14) Allergy Blocker.
- Planned multi-center study: 'Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients with Seasonal Allergic Rhinitis'.
- Company is a development-stage biotech with no approved products or revenue; market cap ~$28M.
- The 20-F annual report (filed 49 days prior) shows 1,608,266 ordinary shares outstanding as of Dec 31, 2025, after two reverse splits in 2025.
- No financial data (revenue, EPS, cash position) or trial start/completion dates were disclosed in this filing.
Financial Impact
No financial figures disclosed; milestone is pre-revenue with no quantifiable near-term revenue impact.
Risk Factors
- Clinical trial may fail to demonstrate safety or efficacy, leading to no regulatory approval.
- Company has no approved products or revenue; relies on future financing which may be dilutive.
- Two reverse splits in 2025 indicate prior stock price distress and potential ongoing capital concerns.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-055510 |
| Document: ea029054002ex99-1.htm | 0001213900-26-055510 |
| Document: 0001213900-26-055510-index-headers.html | 0001213900-26-055510 |
| Document: 0001213900-26-055510-index.html | 0001213900-26-055510 |
| Document: 0001213900-26-055510.txt | 0001213900-26-055510 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 6-K | $9.67 $9.15 | ▼ −5.37% | ▼ −5.13% | $8.96 (−7.37%) |
Oct 2, 2026 25d ago | EFFECT | $9.61 $9.26 | ▲ +3.64% | ▲ +4.32% | $8.96 (+6.80%) |
Sep 22, 2026 4w ago | Press Release | $10.66 $11.16 | ▲ +4.69% | ▲ +5.41% | $8.96 (−15.98%) |
Sep 18, 2026 5w ago | F-1 | $10.90 $10.66 | ▲ +2.20% | ▲ +2.19% | $8.96 (+17.83%) |
Sep 4, 2026 7w ago | Press Release | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Sep 4, 2026 7w ago | 6-K | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Sep 4, 2026 7w ago | 424B5 | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Aug 20, 2026 9w ago | 6-K | $10.30 $10.70 | ▲ +3.88% | ▲ +4.18% | $8.96 (−13.04%) |
Jul 13, 2026 15w ago | 6-K | $13.76 $13.07 | ▼ −4.98% | ▼ −5.38% | $8.96 (−34.88%) |
Jul 2, 2026 16w ago | 6-K | $13.80 $15.21 | ▲ +10.20% | ▲ +9.32% | $8.96 (−35.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers